Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201606-04 Development of Dual targeting Agent for autoimmune Diseases(Immunology, Protein) [12.21.2016]

PRINT

Development and Market Objectives

Development of bispecific antibody inhibiting TNF- α and IL-17, which doing important role in autoimmune and autoinflammatory diseases.

Unmet Medical Need & Target Patients

- Focusing on ankylosing spondylitis and psoriatic arthritis. Especially, ankylosing spondylitis is considered as rare disease. That helps accelerating development.

- The response rate of TNF- α blockade on ankylosing spondylitis is less than 50%. The response rate of IL-17 blockade is much lower than that of TNF-a blockade.

Status

- Developmental candidates are selected

- RCB in preparation

Intellectual Property

- Patent on novel IL-17 antibody was applied and PCT application is scheduled on early December 2017

Competitive Advantages

- One shot Two kill: response rate & Disease modifying compared to TNF- α, IL-17a blockade

- May applied to Non-responder to TNF- α blockade

- Easy to treatment & low cost compared to combination therapy

- May be a choice for TNF- α blockade discontinuation

Indication

autoimmune disease

Research Period

Dec. 9, 2016 ~ Mar. 8, 2018

Company

Y-Biologics Inc.

Developmental Stage

Optimization

Additional Information

Contact Information

Contact
Address Company Name: Y-Biologics Inc.
WebSite Homepage: http://www.ybiologics.com Contact Person: Young-Gyu Cho
E-mail: younggyucho@ybiologics.com Contact: 82-42-716-4979

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code